Herpes Simplex Virus Nucleic Acid Amplification Assay
OQO is the FDA product code for Herpes Simplex Virus Nucleic Acid Amplification Assay, a class II device type, regulated under 21 CFR 866.3305. FDA's definition for this code reads: "A polymerase chain reaction (pcr)-based qualitative in vitro diagnostic test for the detection and typing of herpes simplex virus (hsv) dna using vaginal swab specimens". As of , FDA records hold 12 510(k) clearances under this code, the most recent dated , and one recall.
Classification record
- Product code
- OQO
- Device name
- Herpes Simplex Virus Nucleic Acid Amplification Assay
- FDA definition
- A polymerase chain reaction (pcr)-based qualitative in vitro diagnostic test for the detection and typing of herpes simplex virus (hsv) dna using vaginal swab specimens.
- Regulation
- 21 CFR 866.3305
- Device class
- Class II
- Review panel
- Microbiology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 12
- Ingested recalls
- 1
Clearances, product code OQO
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2014 | 3 |
| 2015 | 3 |
| 2017 | 1 |
| 2018 | 1 |
Applicants with the most clearances
Product code OQO| Applicant | Clearances |
|---|---|
| Eragen Biosciences | 2 |
| Becton Dickinson & Co | 1 |
| Biohelix Corporation | 1 |
| DiaSorin Molecular LLC | 1 |
| Hologic, Inc. | 1 |
| Intelligent Medical Devices, Inc. | 1 |
| Qiagen | 1 |
| Ortho-Clinical Diagnostics, Inc. | 1 |
| Roche Molecular Systems Inc | 1 |
| Seegene Inc. | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
